Clinical trial
Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive…
NCT00171808 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171808 |
|---|---|
| Title | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer |
| Official title | Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer |
| Acronym | deFEND |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 26 |
| Start date | Apr 1, 2005 |
| Primary completion | May 1, 2010 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: